VEGFA and retinopathy of prematurity: During the last decade, the three popular anti-VEGF drugs, bevacizumab, ranibizumab, and aflibercept, have been subjected to clinical trials to establish their efficiency, bioavailability, and functional results in children affected by ROP [64,65,66,67].